投资组合
AbbVie Ventures is focused on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics.\r\n"}}" id="text-8c58e250b0" class="cmp-text">
AbbVie企业专注于早期肿瘤的机会,免疫学、神经科学、眼保健和美学。
积极的投资组合
Accent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.\r\n"}}" id="text-15d89c6842" class="cmp-text">
口音疗法主要是RNA-modifying蛋白质(RMP)生物转化为有前景的新精密治疗癌症。
Expanding the druggable proteome to drug intrinsically disordered proteins.\r\n"}}" id="text-656bf08517" class="cmp-text">
扩大制药蛋白质组药物内在无序蛋白质。
AM–Pharma is developing disease modifying Alkaline Phosphatase therapeutics.\r\n"}}" id="text-4221b33185" class="cmp-text">
修改碱性磷酸酶疗法AM-Pharma发展疾病。
ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.\r\n"}}" id="text-05123d32cb" class="cmp-text">
ApoGen生物技术正在开发一种新的治疗目标持续的DNA突变和肿瘤进化的关键因素。
Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.\r\n"}}" id="text-f7fc272afd" class="cmp-text">
一位医药开发小分子疗法针对持久压力颗粒治疗神经退行性疾病。
Artios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.\r\n"}}" id="text-f94f6c08ac" class="cmp-text">
该制药公司正在开发癌症治疗目标DNA损伤反应途径选择性地杀死癌细胞。
Capsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.\r\n"}}" id="text-677dd702d8" class="cmp-text">
Capsida疗法是创建一个新类的靶向基因治疗中枢神经系统和non-CNS紊乱。
Caraway Therapeutics is developing novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.\r\n"}}" id="text-6dc05d14b1" class="cmp-text">
香菜疗法正在开发新型治疗神经退行性疾病通过调制mitophagy和自噬。
Carisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.\r\n"}}" id="text-f8798dcd42" class="cmp-text">
Carisma疗法发展嵌合抗原Receptor-expressing巨噬细胞为目标并摧毁实体肿瘤。
DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.\r\n"}}" id="text-63d5324bd5" class="cmp-text">
DG药物是使用一种新的药物发现平台确定治疗目标蛋白质降解。
Disc Medicine is developing therapies addressing ineffective red blood cell production in hematologic diseases.\r\n"}}" id="text-fa6105378e" class="cmp-text">
盘医学发展疗法解决无效的红细胞在血液疾病。
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.\r\n"}}" id="text-616c2d047e" class="cmp-text">
EndLyz疗法发展疾病修饰治疗恢复endo-lysosomal功能和废除神经退化在帕金森病(PD)和其它痴呆。
Enthera is developing first-in-class therapeutics for severe autoimmune disorders.\r\n"}}" id="text-212a802fce" class="cmp-text">
Enthera first-in-class疗法发展为严重的自身免疫性疾病。
E-Scape Bio is developing therapeutics against genetic targets for neurodegenerative disease.\r\n"}}" id="text-7ceb496e78" class="cmp-text">
E-Scape生物发展疗法对遗传性神经退行性疾病的目标。
Faze Medicines is pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.\r\n"}}" id="text-c48c79b060" class="cmp-text">
扰药物先锋疗法是基于生物分子冷凝物的开创性的新的科学。
FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.\r\n"}}" id="text-d9a76d0576" class="cmp-text">
FireCyte是一个新兴的生物技术公司发展新的治疗策略集中在小胶质细胞的作用和存在的进行性神经退行性疾病。
Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.\r\n"}}" id="text-a408167d56" class="cmp-text">
智疗法是建立第一个药物发现平台,致力于溶质载体转运蛋白家族。
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology.\r\n"}}" id="text-b1323f8e84" class="cmp-text">
Kojin疗法发展变革的药物是基于一项开创性方法ferroptosis生物学和细胞状态。
Magnolia Neurosciences is developing potent and highly selective neuroprotective therapies.\r\n"}}" id="text-1e8fbaa7eb" class="cmp-text">
木兰神经科学发展强有力的和高度选择性神经保护治疗。
Nitrase Therapeutics is developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.\r\n"}}" id="text-ba4e956dc9" class="cmp-text">
硝酸酶疗法发展药物对一类新发现的酶起有害作用的各种年龄和炎症相关的疾病。
PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.\r\n"}}" id="text-ec70499e42" class="cmp-text">
协议正在开发个性化的基于neoantigen-targeted T细胞过继细胞疗法对癌症。
Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.\r\n"}}" id="text-cad374bed9" class="cmp-text">
Palleon制药是针对glycan-sensing检查站释放先天和适应性免疫反应癌症。
Quanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.\r\n"}}" id="text-51392daaa2" class="cmp-text">
量子疗法是开创性的变构控制RAS调制信号的抑制全RAS-driven癌症类型的范围。
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.\r\n"}}" id="text-73a105a9d8" class="cmp-text">
Ribometrix是一个平台疗法公司发现功能3 d RNA结构为目标的小分子药物来治疗人类疾病。
Ribon Therapeutics is discovering first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress.\r\n"}}" id="text-1266db1d3f" class="cmp-text">
日本梦梦疗法是发现first-in-class小分子抑制剂阻止癌细胞的压力下的生存能力。
Stemson Therapeutics is developing a novel treatment for hair loss, using iPS cells to grow new Dermal Papilla and generate hair follicles de novo.\r\n"}}" id="text-f714b5051d" class="cmp-text">
Stemson疗法正在开发一种治疗脱发,用“诱导多能性”细胞长出新的皮肤乳头并生成毛囊新创。
Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.\r\n"}}" id="text-4f92063f22" class="cmp-text">
Trishula疗法致力于改善癌症患者的结果发展ttx - 030, first-in-class anti-CD39抗体。
Chemoproteomics Stealth NewCo is developing activity-dependent protein ligation technology for quantitative in-cell profiling.\r\n"}}" id="text-5add90b913" class="cmp-text">
Chemoproteomics隐形知识产权转让给新公司正在开发活动依赖性蛋白质定量分析- sensing结扎技术。
Protein Degradation Stealth NewCo is developing small molecule enhancers of the proteasome.\r\n"}}" id="text-69c30b9a46" class="cmp-text">
蛋白质降解隐形知识产权转让给新公司正在开发小分子蛋白酶体的增强剂。
Cell Surfaceome Stealth NewCo is developing novel mass spectrometry methods to decode the cell surface.\r\n"}}" id="text-00ddb6dd92" class="cmp-text">
细胞Surfaceome隐形知识产权转让给新公司发展新型质谱方法解码细胞表面。
前投资
IPO, NASDAQ: ALEC\r\n"}}" id="text-56642cee8c" class="cmp-text">
IPO,纳斯达克:亚历克
Acquired by Gilead\r\n"}}" id="text-539d5c7aee" class="cmp-text">
通过基
Acquired by CSL Behring\r\n"}}" id="text-1749d946b9" class="cmp-text">
收购CSL贝林
IPO, NASDAQ: CRBU\r\n"}}" id="text-1af21081b9" class="cmp-text">
IPO,纳斯达克:CRBU
Merger with Aduro Biotech, NASDAQ: KDNY\r\n"}}" id="text-9a0a87c8fc" class="cmp-text">
合并Aduro生物技术,纳斯达克:KDNY
Acquired by Lilly\r\n"}}" id="text-6e0bd9049b" class="cmp-text">
通过礼来公司
Acquired by Locust Walk Acquisition Corp (SPAC merger), NASDAQ: EFTR\r\n"}}" id="text-36cd674f72" class="cmp-text">
被蝗虫走收购公司收购合并(SPAC),纳斯达克:EFTR
IPO, NASDAQ: XCUR\r\n"}}" id="text-8d25ce1f6d" class="cmp-text">
IPO,纳斯达克:XCUR
IPO, NASDAQ: KALA\r\n"}}" id="text-ddb9c30fb5" class="cmp-text">
IPO,纳斯达克:卡拉
Acquired by Zymergen\r\n"}}" id="text-a23e033657" class="cmp-text">
收购Zymergen
IPO, NASDAQ: MORF\r\n"}}" id="text-91f2c73e11" class="cmp-text">
IPO,纳斯达克:MORF
Acquired by Lilly\r\n"}}" id="text-6c34aa9968" class="cmp-text">
通过礼来公司
Acquired by Amgen\r\n"}}" id="text-eaa88d62a0" class="cmp-text">
安进公司收购
Acquired by Sanofi\r\n"}}" id="text-9a7294c074" class="cmp-text">
赛诺菲安万特收购
Acquired by Gilead\r\n"}}" id="text-027d601aee" class="cmp-text">
通过基
相关内容
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-9b8fdf9f15" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
